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Abstract 
Early and appropriate management of brain insults has significantly reduced 
patient morbidity and mortality. Neuromonitoring, neuroprotection, and 
secondary brain injury prevention are the essential principles of brain injury 
management.  
In this literature review, we have elaborated on the neuroprotective role of 
dexmedetomidine (DEX), predominantly in different animal models of brain 
insults and reports in patients cared for in a neurocritical care setting.  We 
undertook an electronic literature search of articles published in English before 
July 2019. This search resulted in the inclusion of 59 studies from medical 
databanks such as PubMed, Scopus, EBSCO, CINAHL, ISC, and the Cochrane 
Library. The keywords used were brain, α2 agonist, neurocritical care, and 
dexmedetomidine.  
DEX may have a neuroprotective effect in a broad spectrum of brain 
pathologies such as traumatic brain injury (TBI), subarachnoid hemorrhage 
(SAH), ischemic stroke, intracerebral hemorrhage (ICH), and cerebral hypoxia. 
However, its neuroprotective role in status epilepticus (SE) is less clear. Further 
animal and human studies are needed before we could consider DEX as a 
neuroprotective agent in this patient population. Due to its favorable properties 
outlined in this review, DEX could be considered a favorable sedative agent in 
neurocritical care settings. 
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Introduction 
Brain damage is one of the main causes of disability 
and mortality worldwide. Apart from many 
pathologies and neurosurgical interventions, brain 
injury which is most commonly caused by blunt trauma 
to the head can lead to severe brain tissue damage. 
Consequently, some regions of the brain may undergo 
numerous and significant alterations in their vital 
functions (1). 
To ameliorate these damages, prompt and 
appropriate management within the “therapeutic 
window” can be of great value to reduce long-term 
disability and mortality in this patient population.  
The main function of neuroprotective agents in 
the suppression of the biochemical cascades initiated 
by brain injury which ultimately leads to neuronal 
death. These neurodegenerative mechanisms include 
changes in membrane ion permeability, cellular 
1. Anesthesiology Research Center, 
Loghman Hakim Medical Center, 
Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
2. Skull Base Research Center, 
Loghman Hakim Medical Center, 
Shahid Beheshti University of Medical 
Sciences 
3. Shahid Beheshti University of 
Medical Sciences, Tehran, Iran 
4. Loghman Hakim Medical Center, 
Shahid Beheshti University of Medical 









*Corresponding Author:  
Majid Mokhtari, MD, Critical Care 
Department, Loghman Hakim Medical 
Center, Shahid Beheshti University of       
Medical Sciences, South Kargar Ave., 
Kamali St. Tehran, 1333635445, Iran 
Tel/Fax: +98-2155416130 
email: m.mokhtari@sbmu.ac.ir 
Hajiesmaeili et al.                                                                                                               Dexmedetomidine in Neurocritical Care  
                              Journal of Cellular & Molecular Anesthesia (JCMA) 
252 
oxidative stress, mitochondrial dysfunction, increased 
release of excitatory neurotransmitters (particularly 
glutamate), and activation of the inflammatory process. 
Alternation in the membrane ion permeability induces 
Ca2+ influx and this leads to mitochondrial 
dysfunction and ultimately accelerated cell apoptosis. 
Therefore, targeting oxidative stress and 
excitotoxicity, are considered the mainstay of 
neuroprotective strategies (2). 
Dexmedetomidine (DEX) is a selective alpha-2 
agonist with a short half-life and minimal respiratory 
depression. These properties have made DEX a 
suitable drug for the ICU and procedural sedation, as 
well as an adjunctive agent during general and regional 
anesthesia. In addition to its sedative, anxiolytic, 
analgesic, and sympatholytic effects (3, 4). DEX  has 
demonstrated neuroprotective properties (5). Evidence 
from in vitro and in vivo studies have demonstrated the 
neuroprotective effects of DEX against injury caused 
by inflammation, traumatic brain injury, ischemia-
reperfusion, hypoxia, and seizure. Cellular effects, 
mediated by the signaling pathways other than through 
the DEX’s α2-adrenoceptors have also been reported, 
conferring its neuroprotection which has been 
observed in different in vitro and in vivo studies (6,7), 
(Figure 1). 
In this review, we discuss the cellular non-α2-
adrenoceptor-mediated effects of DEX and its 
implication for neuroprotection. 
Method of Study 
We carried out an electronic literature search among 
articles published in the English language before July 
2019. Related publications were retrieved from 
PubMed, Scopus, EBSCO, CINAHL, ISC, and the 
Cochrane Library using keywords including the brain, 
α2 agonist, neurocritical care, and dexmedetomidine.  
Results 
Neuroprotective effects of DEX in traumatic brain 
injury (TBI): Traumatic brain injury (TBI) is a major 
public health problem throughout the world. Due to the 
complexity of symptoms and often unfavorable 
outcome observed in TBI, effective management 
strategies are of paramount importance. The main TBI 
management guidelines focus on intracranial pressure 
(ICP), cerebral perfusion pressure (CPP), mean arterial 
pressure (MAP), cerebral metabolic rate (CMRO2), 
seizure control, and other prophylactic measures (9, 
10).  
A recent study has indicated that TBI inducing 
a complex sequence of pathophysiological changes 
that lead to neuronal death, increase lesion volume, 
inflammation, and microglial activation.  These 
changes result in neurological deficits and cognitive-
motor dysfunction (10). Some studies have shown 
neuronal recovery facilitated by agents such as DEX, 
after brain injury (11). Besides, experimental studies 
have demonstrated the neuroprotective effects of DEX 
in rats following TBI. In an in vivo study on the murine 
model of TBI, researchers exposed mice to varying 
concentrations of DEX (1, 10, or 100 µg/kg 
bodyweight) and assessed cell death in the cortex and 
the hippocampus after 1 hour and 12 hours. They found 
the administration of DEX  at the dose of 100 µg/kg 
reduced cell death and also reduced neuro-axonal 
injury and synaptic degeneration in their animal model 
of TBI (12).  
Brain edema, a specific characteristic of TBI, 
classified as vasogenic or cytotoxic results from an 
increase in brain blood barrier (BBB) permeability due 
to the release of inflammatory and vasoactive 
mediators (13). The effects of DEX administration on 
brain edema reduction has been evaluated in the rat 
model of TBI.  
In the Shen et al. animal study of a weight drop 
rat model, injection of 15 μg/kg DEX two hours after 
TBI, led to reduced modified neurological severity 
score (mNSS), reduced cerebral water content, and 
expression of autophagy proteins (LC3zsz). In their 
model, although the expression of inflammatory 
mediators such as tumor necrosis factor-alpha (TNF-
a), interleukin-1β ­ (IL-1β), interferon-γ (INF-γ), 
interleukin-6 (IL-6) decreased, there was an increased 
expression of tight junction proteins (ZO-1 and 
Claudin-5) and PI3K/Akt/mTOR. It has been 
demonstrated that the PI3K/Akt signaling pathway 
plays important role in the modulation of inflammatory 
pathways, cell survival, and metabolic function. 
Besides, mTOR is a serine/threonine kinase that has a 
central role in the modulation of autophagy. The results 
of this study showed that pretreatment with DEX led to 
PI3K/Akt/mTOR signaling activation in the brain 
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areas of the rat following TBI (14). 
In another study administration of DEX 
alleviated inflammation induced by TBI. The 
mechanisms underlying DEX’s action following the 
induction of TBI were increased expression of the 
apoptotic speck-containing protein (ASC), activation 
of caspase1, and processing of IL-1β and IL-18 and 
nucleotide-binding oligomerization domain-like 
receptor family pyrin domain-containing 3(NLRP3) 
signaling These findings suggested that NLRP3-
inflammasome plays a key role in the inflammatory 
process following TBI and might be a target for 
treatment (15). 
DEX can inhibit stress response reactions and 
maintain stable cardiovascular and respiratory function 
(16). Tanget et al reported patients with severe TBI 
(GCS = 6) who had a history of chronic alcohol abuse. 
Theses patient received an infusion of DEX 0.5 
mcg/kg/h titrated ultimately to 1.5 mcg/kg/h for 8 days. 
They concluded that DEX has an anxiolytic effect in 
this patient population. (17). The neuroprotective 
effect of DEX decreases the state of hyperarousal via 
central α2-receptors activity in the CNS. Furthermore, 
DEX acts on the differential GABA receptor and have 
beneficial anxiolytic effects (18). 
DEX in Subarachnoid Hemorrhage (SAH): 
Subarachnoid hemorrhage (SAH) is bleeding in the 
subarachnoid space between the pial and arachnoid 
membranes. It has been demonstrated that structural 
changes such as vasospasm and hyperplasia of the 
arterial walls can complicate SAH (19). 
Ayoglu and colleagues studied the efficacy of 
two doses of DEX (5 and 10 µg/kg) 1 and 24 hours 
after SAH, on vasospasm and oxidative stress in rats. 
They found that malondialdehyde (MDA) and mean 
wall thickness (MWT) decreased in the treatment 
group. Also, MDA levels and MWT and proliferating 
cell nuclear antigen (PCNA) expression were lower in 
the treatment group (10 µg/kg). These results 
suggested that pretreatment with DEX in a dose-
dependent fashion (10 µg/kg) leads to reducing 
oxidative stress and vasospasm in the rats' model of 
SAH (20).  
Another study investigated the efficacy of DEX 
(5 μg/kg/h) for 2 hours and 48 hours after SAH, on the 
hippocampus vasospasm and evaluated the 
biochemical markers such as MDA levels, the activity 
of XO (xanthine oxidase), and SOD (superoxide 
 
Figure 1. Schematic diagram showing the mechanism action of DEX in brain injury. 
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dismutase) in rabbits. Administration of DEX led to 
decreased MDA levels and XO activity and increased 
SOD activity, suggesting attenuation of vasospasm in 
the hippocampus of their rabbit model of SAH (5).  
Song and his colleagues investigated treatment 
with DEX on vasospasm and measured related 
biomarkers such as IL-6 in the SAH model of rats. 
They found a correlation between IL-6 levels and the 
occurrence of vasospasm in their SAH animal model 
(21).  
Besides,  DEX ameliorated vasospasm 
significantly and improved neurological outcomes in 
rat models of SAH which was thought to occur by 
reducing IL-6 levels in their CSF (22).  In another rats’ 
model of SAH, Li et al. showed higher doses of DEX 
(100 µg/kg body weight) compared to the lower doses 
(10 and 50 µg/kg body weight) resulted in better 
neurological scores, reduce subarachnoid hemorrhage, 
lesser cerebral edema and more reduction in the 
inflammatory interleukins such as IL-1β, IL-6, and 
TNF-α (23).   
Yin and colleagues examined the 
neuroprotective effect of DEX in the early brain injury 
(EBI) after SAH and investigated its mechanism of 
action. They found that administration of DEX reduced 
neurological deficits, attenuated brain tissue edema, 
decreased the permeability of the blood-brain barrier 
(BBB) and the level of IL-1β, IL-6, and TNF-α (24). 
DEX also reduced cell apoptosis at 24 hours after SAH 
in rats. Particularly, it inhibited toll-like receptor 4 
(TLR4)/nuclear factor-κB (NF- κB) [(TLR4/NF-κB)] 
signaling and NLRP3 inflammasome activation. It has 
been demonstrated that the TLR4/NF-κB signaling 
plays an important role in the release of IL-1β, IL-6, 
and TNF-α in EBI after SAH. The accelerated release 
of these inflammatory markers led to BBB disruption 
and cell apoptosis (24).  
It seems that the neuroprotective effects of DEX 
in the rats' model of subarachnoid hemorrhage may be 
mediated in part through the extracellular signal-
regulated kinase (ERK) (25). In a retrospective review 
by Okazaki and colleagues, the administration of DEX 
in the first 24h after admission was associated with 
favorable neurological outcomes in patients with SAH 
(26). 
In conclusion, experimental studies, 
predominantly in animal models of SAH, have shown 
to improve neurological outcome. 
DEX in Ischemic Stroke: Prior studies have 
reported the neuroprotective effect of DEX in cerebral 
ischemia. In vitro evidence suggests that DEX plays an 
important role in the process of ischemic 
preconditioning in hippocampal slices exposed to 
oxygen and glucose deprivation (OGD); this may be 
closely linked to increased phosphorylation of focal 
adhesion kinase (FAK) and pro-caspase-3 (27). 
Treatment with low dose DEX before and following 
the induction of cerebral ischemia prevented delayed 
neuronal cell death in the hippocampal CA3 region and 
dentate hilus of the gerbil, which is thought to occur by 
inhibiting the release of catecholamines (28).  
Goyagi and colleagues investigated the effect of 
co-administration of lidocaine and DEX in rats 
following forebrain ischemia. They examined 
neurological function scores, counted the ischemic 
cells, and measured levels of extracellular glutamate 
and norepinephrine concentration in CA1 of the 
hippocampus. The results showed that co-
administration of lidocaine and DEX in rats decreased 
the neurological deficit and ischemic cells in forebrain 
ischemia (29). Besides, preconditioning with DEX 
reduced permeability of the blood-spinal cord barrier 
(BSCB) in spinal cord ischemia-reperfusion injury in 
rats through inhibition of matrix metalloproteinase-9 
(MMP-9), and enhanced the binding of angiopoietin-1 
(Ang1) to Tie2 receptor in endothelial cells (30). 
In recent years, accumulating reports have 
indicated neuroinflammation to play a key role in 
cerebral ischemia. Some studies have shown that DEX 
possesses a potent anti-inflammatory effect via 
inhibition of inflammatory cytokines and mediators 
(31, 32).  
Jiang and colleagues demonstrated the 
protective effects of DEX on the experimental 
craniocerebral injury in rats via decrease TNF-α and 
IL-2 levels (33).  DEX has anti-inflammatory action 
through the inhibition of the TLR-4/NF-κB and NF-κB 
pathway in ischemia-reperfusion injury in rats 
resulting in improved neurological deficit (34). Other 
studies showed DEX to attenuate significantly the 
damage to rat brains after Ischemia-reperfusion 
evaluated by NDS scores (vision, cognition, corneal 
reflex, m¬otor activity and seizure episodes with 
scores of 0 = normal and 100 = brain death). Their 
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results showed that treatment with DEX decreased the 
neurological deficit, NDS scores, S100B, and MDA 
levels and inhibited the expression of intracellular 
adhesion molecule-1 (ICAM-1) and NF- κB (35). It has 
also been reported that DEX increases the ratio of anti-
apoptotic to pro-apoptotic factors attenuating apoptosis 
via inhibiting activation of its intrinsic signaling 
pathways (36). 
DEX and Intracerebral hemorrhage (ICH): 
Cerebral hemorrhage may result in irreversible loss of 
functions of the nervous system. Learning and memory 
deficits are among the most common sequelae of ICH 
(37, 38). Some of the mechanisms underlying the 
neuronal loss of function are via decreased expression 
of brain-derived neurotrophic factor (BDNF) and 
Neuroglobin (NGB) in the brain (39).  
Hwang et al. examined the effects of DEX on 
learning and spatial memory and apoptosis of neurons 
in the hippocampus after the induction of ICH in rats. 
The results showed DEX administration in ICH to 
improve learning and spatial memory with a better 
histopathological outcome via suppressing cell 
apoptosis and enhancing neuronal BDNF and TrkB 
gene expression in rats (40).  
DEX and Status Epilepticus (SE): Status epilepticus 
(SE) is a medical emergency that can result in 
permanent neurobiological damage and severely affect 
cognitive abilities. Besides, SE patients show 
depression, anxiety, and other signs of mental 
disorders, which significantly diminish the quality of 
patients' life (41, 42). Some studies have shown that SE 
induced a range of morphological and physiological 
changes in the brain, such as neurogenesis, 
synaptogenesis, imbalance of excitatory-inhibitory 
signals, and neuroinflammation (43–45).   
In experimental studies, pretreatment with DEX 
(3/µg/kg, subcutaneously) suppressed epileptic 
activity and neuronal damage of the principal cell 
layers of the hippocampus in the Kainic acid (KA) 
model of status epilepticus in rats (46). It has been 
demonstrated that DEX could increase the seizure 
threshold in the cocaine model of seizure in rats by 
reducing the response of the extracellular 
dopaminergic neurotransmitter to cocaine (47).  
In another animal study, investigators have 
shown that DEX has an anticonvulsant effect on the 
seizures induced by nerve agents in rats. Wang et al. 
reported that DEX effectively reduced the frequency 
and duration of seizures and diminished the level of 
glutamate (Glu) and the ratio of malondialdehyde 
(MDA) and glutathione (GSH/MDA) in the 
hippocampus in the model of electrical stimulation of 
the amygdala in rats. These results demonstrated the 
anti-oxidative properties of DEX in seizures (48).  
In another study, the efficacy of DEX was 
investigated regarding cognition and 
neuroinflammation in the hippocampus of rats, 
following convulsive status epilepticus (CSE). These 
results showed DEX to have anticonvulsant effects as 
evidenced by decreased seizure severity.  
Also, DEX enhanced spatial cognitive function 
and long-term potentiation (LTP) amplitude in the CSE 
model of rats. DEX has also demonstrated some 
antioxidant effects through the reduction of serum IL-
1β, TNF-α, and S-100β levels and increased BDNF 
levels. Immunohistochemistry results in this study 
showed that the expression of α7-nicotinic 
acetylcholine receptor (α7-nAChR) and IL-1β 
decreased in the hippocampus in this model of seizures 
(49).  
Kurosawa et al. reported that DEX depresses 
glutamatergic transmission, but does not influence 
inhibitory synaptic transmission via the GABA A-
receptor in the hippocampus of rats. Furthermore, type 
1 and type 2 receptors of imidazoline mediated the 
effect of DEX on the epileptiform discharge (50). 
Miriski et al. showed the effects of DEX on the seizures 
model induced by pentylenetetrazole (PTZ) in rats. 
They found that treatment with DEX had a 
proconvulsant effect in the PTZ model of rats (51). 
Other investigations regarding the effect of 
DEX on seizure are inconsistent with these results. For 
example, Halonen et al. studied the efficacy of DEX 
(1, 10, or 100 µg/kg intravenously) on seizure 
induction index (SII) during 3.5% enflurane anesthesia 
in cats. These findings showed that treatment with high 
doses of DEX (10 and 100 µg/kg) increased SII and, as 
a result, decreased seizure threshold during enflurane 
anesthesia. In clinical practice, Kubota et al. reported 
an infant who was sedated by DEX (0.625 µg/kg/h) 
during artificial ventilation and was monitored for 
epileptic seizures and non-epileptic abnormal 
movements by EEG. They observed induced epileptic 
activity in this infant during artificial ventilation after 
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the administration of DEX (52).  
In the study of Talke and colleagues on five 
patients with uncontrollable seizures, infusion of DEX 
0.5 mg/kg for 60 minutes didn’t have a significant 
effect on intractable epileptiform discharges (53). 
DEX and Cerebral Hypoxia: Cerebral hypoxia often 
occurs following ischemic shock, cardiac arrest, or 
complicated cardiac surgeries (54). This results in 
cognitive impairment, decreased motor control, 
seizures, and may progress to coma and brain death. It 
has been demonstrated that cerebral hypoxia increases 
the generation of reactive oxygen species (ROS) in 
neural tissue. Brain hypoxia requires immediate 
intervention to reduce the possibility of irreversible 
brain damage (55, 56). Experimental studies have 
shown the neuroprotective effect of DEX in cerebral 
hypoxia (57).  
In vitro studies have indicated that DEX exerts 
protective effects on neural tissue under hypoxic 
conditions. DEX displayed a preconditioning effect 
against hypoxic injury in hippocampal slices during 
oxygen and glucose deprivation (OGD). Also, DEX 
reduced cell apoptosis in the hippocampus when 
administered before the induction of hypoxia (55). 
It has been demonstrated that the administration 
of DEX decreases brain hypoxia-induced ischemia in 
neonatal rats. This effect may be mediated through the 
inhibition of inflammatory pathways in the ischemic 
cerebral tissues (58). Eser et al. examined the 
neuroprotective effect of DEX on the hippocampus and 
dentate gyrus following transient global cerebral 
ischemia/reperfusion injury in rats. The results 
indicated DEX to reduce MDA and NO levels, but the 
activities of SOD and CAT increased. Besides, the 
TNF-α level and the number of apoptotic neurons 
significantly decreased after treatment with DEX (56).  
Another study examined the effects of DEX on 
neurodegeneration, biomarkers of oxidative stress, and 
inflammatory markers after the induction of hyperoxia 
in neonatal rats. The results of this study showed DEX 
to significantly reduce neurodegeneration in various 
regions of the rat’s brain. DEX also restored the ratio 
of reduced to oxidized glutathione and attenuated the 
levels of malondialdehyde and downregulated IL-1𝛽 
mRNA expression and protein levels in rat’s neonatal 
brain. DEX provided neuroprotective effects in this 
model, via suppression of the oxidative stress-
inflammatory cytokine signaling pathways. Based on 
these data, DEX has been proposed to have a 
neuroprotective role in neonatal rat’s model of hypoxia 
(59). 
Conclusion 
In this review, we have highlighted the neuroprotective 
properties of DEX in different brain pathologies. The 
data in patients with TBI suggest DEX has 
neuroprotective effects through suppression of the 
inflammatory pathway. In patients with SAH and 
cerebral hypoxia, our search indicated DEX’s 
potentials to leads to improved neurological outcomes, 
mediated in part through suppression of the 
inflammatory and oxidative pathways. In the ischemic 
stroke population, DEX exerts a potent anti-
inflammatory property via the inhibition of 
inflammatory mediators and intrinsic apoptotic 
signaling pathways. In the ICH patients, DEX 
administration improved cognitive function via 
suppressing cell apoptosis and enhancing neuronal 
BDNF signaling and TrkB gene expression. However, 
data regarding the effects of DEX on seizure appear to 
be conflicting, with some studies showing heightened 
seizure threshold via suppression of the inflammatory 
and oxidative stress pathways and others indicating 
decreased seizure threshold by unknown mechanisms. 
Overall, because of its analgesic, anxiolytic, and anti-
inflammatory properties, DEX can be considered a 
favorable sedative agent in neurocritical care settings. 
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